Summary China shares post second straight daily loss Thursday, led by pharma, banking and auto counters.
HONG KONG (Reuters) -Investigation into rampant bribery in the pharmaceutical and medical services sector with a fresh three-month probe slated to begin on Thursday, the official Xinhua news agency reported.
The investigation by the State Administration for Industry and Commerce (SAIC), a regulator in charge of market supervision, is aimed at stamping out bribery, fraud and other anti-competitive practices in various sectors, Xinhua said.
China shares posted a second straight daily loss on Thursday, led by pharmaceutical, banking and auto counters after official media reported that regulators will likely target these sectors as anti-trust investigations intensify.
The CSI300 of the leading Shanghai and Shenzhen A-share listings ended down 1.2 percent at 2,321.6. The Shanghai Composite Index shed 0.9 percent.
China is intensifying its investigation into bribery in the pharmaceutical and medical services sector with a fresh three-month probe slated to begin on Thursday, the Xinhua news agency reported.
China s powerful price regulator could target the petroleum, telecommunications, banking and auto sectors next in its investigations into violations of the country s anti-trust laws, state media quoted a senior official as saying on Thursday.
